




## Conformal RT and 3D-CRT planning



Dott. Paola Chiovati , Medical Physicist, CRO Aviano  
E-mail : [pchiovati@cro.it](mailto:pchiovati@cro.it)

## WORLD HEALTH ORGANIZATION





## PATIENT SET UP CRT 3D-CRT

## POSITIONING AND IMMOBILIZING

Positioning is not immobilization


confortable → maintain the position for long time

Help the OAR sparing




# PATIENT SET UP CRT 3D-CRT

## POSITIONING AND IMMOBILIZING



Immobilization in CRT:  
Desirable

Immobilization In 3D-CRT:  
customized to the patient





## PATIENT SET UP CRT 3D-CRT

Immobilization In 3D-CRT:  
customized to the patient



# Basic CRT

Immobilization: Desirable




Skin marker





# Basic CRT



**Field Shape and dimension drawn on simulation films**






# Basic CRT




Contour individual slices

Manual Calculation (1-D )




Isodose on central slice





Basic CRT  
optional



few CT slices optional




Dose calculation 2-D (slice)  $\pm$  inhomogeneity

# Image Acquisition 3D-CRT

adjacent thin slices **CT slices**




Skin Marker



## Image Acquisition 3D-CRT


coordinate system on the patient,



THE CT coordinate system and origin IS EXPRESSED BY LASERS



## Image Acquisition 3D-CRT




The coordinate system of the equipment must match with the coordinate system on the patient, and the two origin must match.

Radiopaque Marker over the skin marker in order to see them in CT acquisition




# Image Acquisition3D-CRT




# Contouring in 3D-CRT

IMAGING




TPS or contouring  
Station




In TC SLICES AND A 3D VOLUME RECONSTRUCTED FROM SLICES, **Radiation Oncologist or Radiation Therapy Technologist** countour:

- GROSS TUMOR VOLUME (GTV)
- CLINICAL TARGET VOLUME (CTV)
- ORGANS AT RISK

## Image registration with other Modality for Contouring in 3D-CRT



Optional in 3D-CRT  
Mandatory in Advanced 3D-CRT



## PTV : PLANNING TARGET VOLUME

PTV is a geometric concept designed to ensure that the radiotherapy prescription dose is the dose delivered to the CTV.

PTV= CTV+IM+SM:

the internal margin (IM), that takes in account the variation of CTV that may result from:


- ❖ respiration
- ❖ different filling of bladder and rectum
- ❖ heart beat
- ❖ intestine movements
- ❖ ...

they are physiological variations which are difficult or impossible to control.

the set up margin (SM), that takes in account the overall inaccuracy and lack of reproducibility in patient positioning, in beam alignment and field dimensions during a session and through all treatment session. they depends on:


- ❖ variation in patient positioning
- ❖ mechanical uncertainties of the equipment
- ❖ dosimetric uncertainties
- ❖ transfer set up errors from CT or simulator to the treatment unit
- ❖ human factors





### PRV: PLANNING ORGAN AT RISK VOLUME


in some specific circumstances, it is necessary to add a margin analogous to the PTV margin around an OR to ensure that the organ cannot receive a higher than safe dose; this gives a planning organ at risk volume. This applies to an organ such as the spinal cord, where damage to a small amount of normal tissue would produce a severe clinical manifestation.



Commissioning



TPS




# CT Calibration

## IMAGING WITH X-RAY COMPUTED TOMOGRAPHY

in order to calculate the doses, the

TPS u  
density  
differen



|  | Electron density | (HU) 120kV |
|--|------------------|------------|
|  | 1.695            | 1229.5     |
|  | 1.466            | 827.6      |
|  | 1.278            | 460        |
|  | 1.105            | 240.1      |
|  | 1.097            | 223.3      |
|  | 1.072            | 92.2       |
|  | 1.047            | 30.4       |
|  | 1.000            | 2.7        |
|  | 0.988            | 7.325      |
|  | 0.958            | -39.4      |
|  | 0.930            | -88.2      |
|  | 0.420            | -554.2     |
|  | 0.269            | -706.2     |

BR-12 Breast

AP6 Adipose

LN - 450 Lung

LN - 300 Lung

CALIBRATION CT N° VS RELATIVE ELECTRONIC or MASS DENSITY




Commissioning



TPS

CALIBRATION CT NUMBER VS RELATIVE  
ELECTRONIC or MASS DENSITY




3D volume and slices  
with contours of OAR  
and Target




3D-CRT Planning

# ISOCENTER




IN THE 3DCRT TREATMENT THE ISOCENTER IS LOCATED GENERALLY AT THE CENTER, OR IN THE CENTRAL PART, OF THE PTV (SAD TECNIQUE)





ISOCENTER

...origin could be different from isocenter



# BEAM ENERGY





## BEAM ENERGY

preferably, small depth target, low energy, big depth target, high energy (except low electron density tissues – for example lung)


because... “the algorithms have different accuracy particularly in low hounsfield units (low density) regions” ....6 MV photons may be the prudent choice.

avoid energy  $\geq 8$  MV in the presence of CIED or Pacemaker because the production of neutron could damage electrical devices

Plan dose: no coplanar (CT 1)  
No dose  
Position: 17.45 0.00 18.32 cm  
CT: -1000 HU



GANTRY ANGLE



R


L

COPLANAR FIELD



CT: CT 1

Plan dose: no coplanar (CT 1)  
No dose  
Position: 16.84 0.00 15.61 cm  
CT: -1000 HU



A

R

L

GANTRY ANGLE

iso

COPLANAR FIELD




CT: CT 1



GANTRY ANGLE

BEV


BEAM EYE VIEW



GANTRY ANGLE



BEV

BEAM EYE VIEW








ISOCENTER PLANE

Collimator Angle  
and Shielding




# GANTRY ANGLE










GANTRY ANGLE




COUCH ROTATION



NO COPLANAR FIELD




# Collision




CT: CT 1  
Sagittal: 1.09 cm




## FIELD DIMENSION



at any depth (...) the field dimensions correspond to the 50% of the dose on the beam axis ...




ICRU 50: ... “a certain degree of heterogeneity, today in the best technical and clinical conditions, should be +7% and -5% of  $D_{\text{PRESCR.}}$ ”



in both directions (x and y) the field edge must be bigger than the PTV dimension of 5÷10 mm

## EXAMPLE WITH MLC



## EXAMPLE WITH MLC

60  
59  
58  
57  
56  
55  
54  
53  
52  
51  
50  
49  
48  
47

Y2

X1

iso


14  
13  
12  
11  
10  
9  
8  
7  
6  
5





# DOSE PRESCRIPTION

FROM ICRU 50



## THE ICRU REFERENCE POINT


3.3 general recommendations for reporting doses:

the doses **at or near the center** of the planning target volume as well as the maximum and the minimum dose to the PTV shall be reported ...

3.3.1 the ICRU reference point

the ICRU reference point shall be selected according to the following general criteria:

- the dose at the point should be clinically relevant and representative of the dose throughout the planning target volume
- the point should be easy to define in a clear and unambiguous way
- the point should be selected where the dose can be accurately determined (physical accuracy)
- the point should be selected in a region where there is no steep dose gradient




a treatment planned in SAD condition, is usually normalized and prescribed at isocenter that became the ICRU reference point

....but the isocenter and the prescription point could be different.


- is this case normaliation must match with the prescription point that became the ICRU reference point

# WEDGE


in some situations, there is the necessity to introduce a beam modifier to correct the isodoses curves, to maintain a correct dose distribution on PTV



# WEDGE




# WEDGE






# PHYSICAL WEDGE



# FiF TECHNIQUE



| Group                               | Field ID | Technique | Machine/Energy | MLC | Field Weight | Scale      | Gantry Rtn [deg] | Coll Rtn [deg] |
|-------------------------------------|----------|-----------|----------------|-----|--------------|------------|------------------|----------------|
| <input checked="" type="checkbox"/> | 307      | STATIC-I  | 600 C - 6X     |     | 0.930        | Varian IEC | 307.0            | 359.0          |
| <input checked="" type="checkbox"/> | 131      | STATIC-I  | 600 C - 6X     |     | 0.930        | Varian IEC | 131.0            | 2.0            |



## FiF TECHNIQUE


Visualization  
of D95%




Visualization  
of D95%



| FIELD | WEIGHT |
|-------|--------|
| 307_1 | 45.60% |
| 131_1 | 45.60% |
| 307_2 | 5%     |
| 131_1 | 5%     |



## BEAM WEIGHT



75% BEAM WEIGHT= THAT BEAM GIVE THE 75% OF THE PRESCRIBE DOSE AT THE PRESCRIPTION POINT

# BEAM WEIGHT

SP1 \*Patient name: 3D-CRT left breast ID: 3D-CRT left breast Case: CASE 1 RayStation ICTP Not For Clinical Use v8.1.1.8

Planning ▾ Patient Data Patient Modeling ▾ **Plan Design** ▾ Optimization ▾ Evaluation ▾ QA ▾ Delivery ▾

Plan Setup **3D-CRT** Electron Proton TEST2019 TEST2019 Plan Dose

Conform all beams Move isocenter Rotate gantry Edit virtual jaws  
 Conform MLC Center beam in field Rotate collimator Sync Y-jaws  
 Set to midplane Rotate couch Edit MLC and jaws

TREAT AND PROTECT ISOCENTER BEAM EDITING APERTURE SHAPES

BEV 2D 2D BEV DVH 2D DVH

Plan dose: TEST2019 (CT 1)  
 Clinical: Collapsed Cone v5.0  
 Position: 10.26 0.00 -16.16 cm  
 CT: 993 HU  
 Dose: -  
 30.0° at 0° - 1VW30  
 Max Dose 5555  
 Beam: 303  
 CT: CT 1  
 Segment: 1/1

3D Room View 2D

Plan: TEST2019 / Beam Set: TEST2019  
 % of 5000 cGy  
 110  
 107  
 105  
 100  
 95  
 90  
 80  
 70  
 60  
 50  
 25  
 0  
 30.0° at 0° - 1VW30  
 Max Dose 5555  
 CT: CT 1  
 Generic CT  
 Sagittal: -0.01 cm

CT: CT 1  
 Generic CT  
 Transversal: 0.00 cm  
 Slice 46/87

Plan dose: TEST2019 (CT 1)  
 Clinical: Collapsed Cone v5.0  
 % of 5000 cGy  
 110  
 107  
 105  
 100  
 95  
 90  
 80  
 70  
 60  
 50  
 25  
 0  
 30.0° at 0° - 1VW30  
 30.0° at 0° - 1VW30  
 30.0° at 0° - 1VW30  
 CT: CT 1  
 Generic CT  
 Sagittal: -0.01 cm

2D Dose Statistics Clinical goals

Plan dose: TEST2019 (CT 1)  
 Clinical: Collapsed Cone v5.0  
 % of 5000 cGy  
 110  
 107  
 105  
 100  
 95  
 90  
 80  
 70  
 60  
 50  
 25  
 0  
 30.0° at 0° - 1VW30  
 30.0° at 0° - 1VW30  
 30.0° at 0° - 1VW30  
 CT: CT 1  
 Generic CT  
 Coronal: 0.01 cm

Beams Control Points Treat and Protect **Beam Weighting** Beam Dose Specification Points

☐ Weight MU ☒ Weight dose

| No. | Name | Description | MU/fx  | Beam dose to POI iso [cGy] | Clamp MU                 | Relative values Weight | Dose weight [%] | iso [cGy] | DSP [cGy] |
|-----|------|-------------|--------|----------------------------|--------------------------|------------------------|-----------------|-----------|-----------|
| 1   | 303  |             | 111.84 | 2500                       | <input type="checkbox"/> | <input type="range"/>  | 50.00           | 2500      | 2444      |
| 2   | 304  |             | 116.80 | 2500                       | <input type="checkbox"/> | <input type="range"/>  | 50.00           | 2500      | 2385      |

STUDENTS

Plan1

Plan2

Plan1

CT\_1libero

Registered Images

CT\_2

CT\_breath.hold

CT\_1

BODY

Breast\_R

CTV\_High

Heart

LAD

Lung\_L

PTV

Skin

User Origin

Reference Points

PTV


Dose

Fields

300

MLC

130



| Fields                              | Dose Prescription | Field Alignments | Plan Objectives | Optimization Objectives | Dose Statistics           | Calculation Models | Plan Sum            |              |              |               |
|-------------------------------------|-------------------|------------------|-----------------|-------------------------|---------------------------|--------------------|---------------------|--------------|--------------|---------------|
| Show DVH                            | Structure         | Approval Status  | Plan            | Course                  | Volume [cm <sup>3</sup> ] | Dose Cover. [%]    | Sampling Cover. [%] | Min Dose [%] | Max Dose [%] | Mean Dose [%] |
| <input checked="" type="checkbox"/> | Lung_L            | Approved         | Plan1           | STUDENTS                | 1206.3                    | 100.0              | 100.0               | 0.5          | 93.3         | 9.7           |
| <input checked="" type="checkbox"/> | Heart             | Approved         | Plan1           | STUDENTS                | 613.1                     | 100.0              | 100.0               | 0.2          | 76.7         | 3.1           |
| <input checked="" type="checkbox"/> | PTV               | Approved         | Plan1           | STUDENTS                | 567.8                     | 100.0              | 100.0               | 54.6         | 107.4        | 100.3         |
| <input checked="" type="checkbox"/> | LAD               | Approved         | Plan1           | STUDENTS                | 1.3                       | 100.0              | 100.6               | 1.6          | 68.1         | 14.1          |
| <input checked="" type="checkbox"/> | CTV_High          | Approved         | Plan1           | STUDENTS                |                           |                    |                     |              |              |               |

DVHs are usually displayed in the form of volume ("per cent of total volume" or in cc) that received the dose  $\geq$  the value in abscissa (% or Gy).

The main drawback of the DVHs is the loss of spatial information that results from the condensation of data when DVHs are calculated.

## Homogeneity Index (“PTV DVH steepness”)

$$HI = \frac{D1\% - D99\%}{D_{prescription}}$$

DX% = Dose at X% of PTV Volume

## Conformity number (“how reference dose fit the PTV”)

$$CN = \frac{TV_{RI}}{TV} \times \frac{TV_{RI}}{V_{RI}}$$

RI = reference isodose

V<sub>RI</sub> = reference isodose volume

TV = target volume

TV<sub>RI</sub> = target volume covered by reference isodose  
= intersection of TV and V<sub>RI</sub>

## Healty Tissue Conformity Index

$$HTCI = \frac{TV_{RI}}{V_{RI}}$$

RI = reference isodose

V<sub>RI</sub> = reference isodose volume


TV = target volume

TV<sub>RI</sub> = target volume covered by reference isodose  
= intersection of TV and V<sub>RI</sub>

DRR

## Digitally Reconstructed Radiographs

A digitally reconstructed radiograph (DRR) is the artificial version of an X-ray image. It can be computed from CT data and is a two-dimensional (2D) image simulating a normal X ray image or fluoroscopic image.




A digitally reconstructed radiograph (DRR) BECOME THE REFERENCE IMAGES FOR THE SET UP OF THE PATIENT BEFORE THE TREATMENT



## METAL ARTIFACTS

Metal Prostheses  
must be avoid





Contour artifact and assign a  
new density value, generally  
water

the impact of dental metal artifacts on head and neck imrt dose distributions (Radiotherapy and Oncology 79 (2006) 198–202)


REPORT 63 AAPM (2003): Dosimetric considerations for patients with HIP prostheses undergoing pelvic irradiation


# BREAST

Left Anterior Descending artery  
(LAD)




Patients with breast cancer can be (very) long term survival patients, and this is a good endpoint in breast cancer treatment. However, just because long-term survival patients, the radiation treatment can stimulate the development of radiation-induced cancers, which includes second primaries in the contralateral breast.







## 3D-CRT PLANNING: BREAST CASE



| PTV | Prescription | N° fraction | Dose for Fraction |
|-----|--------------|-------------|-------------------|
| PTV | 50 Gy        | 25          | 2 Gy              |

| OAR                  | Dmax<br>Gy | Dmean<br>Gy | Constraints                     | Other, if it is possible         |
|----------------------|------------|-------------|---------------------------------|----------------------------------|
| LAD                  | 20         |             |                                 |                                  |
| Heart                | 20         | 5           | $V5\% < 25\%$                   | $Dmean < 3Gy$                    |
| Lung                 |            |             | $V15Gy < 15\%$<br>$V5Gy < 42\%$ | Isodose 50% 2cm from thorax wall |
| Controlateral Breast | 3%         |             |                                 |                                  |


Standard treatment technique: 2 tangential fields with wedge or FeF technique




3D-CRT PLANNING: BREAST CASE



## 3D-CRT PLANNING: BREAST CASE

....pair of tangential radiation beams with wedges....






## 3D-CRT PLANNING: BREAST CASE









## 3D-CRT PLANNING: BREAST CASE


|     |           |       |
|-----|-----------|-------|
| LAD | $D_{MAX}$ | 20 Gy |
|-----|-----------|-------|






## 3D-CRT PLANNING: BREAST CASE

|     |           |       |
|-----|-----------|-------|
| LAD | $D_{MAX}$ | 20 Gy |
|-----|-----------|-------|



## 3D-CRT PLANNING: BREAST CASE

# Controlateral Breast is OAR




# 3D-CRT PLANNING: BREAST CASE

PRESCRIPTION POINT = ISOCENTER



# 3D-CRT PLANNING: BREAST CASE

PRESCRIPTION POINT  $\neq$  ISOCENTER





# 3D-CRT PLANNING: PANCREAS CASE

RayStation 8B SP1 \*Patient name: 3D-CRT\_PANCREAS ID: 3D-CRT\_PANCREAS Case: CASE 1 RayStation IT Italiano (Italia) Guida v8.1.1.8

Automated Planning Patient Data **Patient Modeling** Plan Design Optimization Evaluation QA Delivery

Image Registration **Structure Definition** Deformable Registration test1 test1 Plan Dose

ROI Tools POI Tools Approval Fusion Select layout New ROI geometry CURRENT ROI Stomach\_ICTP Brush Smart brush Smart contour Spline Polygon Freehand CONTOURING Show Accept current Accept all INTERPOLATION Mode: 2D 3D Deform Translate Rotate Scale Region growing 3D EDITING

ROI Targets (2) PTV54\_ICTP PTV45\_ICTP Organs at risk (9) Stomach\_ICTP Spinal\_Cord\_ICTP SmallBowel\_ICTP Lung\_ICTP Liver\_ICTP KidneyRT\_ICTP KidneyLt\_ICTP Heart\_ICTP External\_ICTP

2D 3D DOSE IS NOT CALCULATED WITH CURRENT DOSE ENGINE VERSION. Plan dose: test1 (CT 1) Clinical: Collapsed Cone v4.0 % of 4500 cGy 110 107 105 100 95 90 80 70 60 50 25 0 CT: CT 1 Anonymized Transversal: -6.00 cm Slice 22/61 0 2 4 6 8 cm


2D 3D DOSE IS NOT CALCULATED WITH CURRENT DOSE ENGINE VERSION. Plan dose: test1 (CT 1) Clinical: Collapsed Cone v4.0 % of 4500 cGy 110 107 105 100 95 90 80 70 60 50 25 0 CT: CT 1 Anonymized Sagittal: -0.21 cm 0 5 10 15 20 cm

2D 3D DOSE IS NOT CALCULATED WITH CURRENT DOSE ENGINE VERSION. Plan dose: test1 (CT 1) Clinical: Collapsed Cone v4.0 % of 4500 cGy 110 107 105 100 95 90 80 70 60 50 25 0 CT: CT 1 Anonymized Coronal: 1.87 cm 0 5 10 15 20 cm

Image Set Library Primary: CT 1 Secondary: - Set as primary Set as second



# 3D-CRT PLANNING: PANCREAS CASE




**Prescription**

**N°**

45 Gy


54 Gy



1 PLAN 25 FR ON PTV 45+ 2 PLAN 5 FR ON PTV 54


| OAR                                   | Dmax Gy | Dmean Gy | Constraints                             | Other, if it is possible |
|---------------------------------------|---------|----------|---|--------------------------|
| Spinal coord                          | 50      |          |   | Dmax<45Gy                |
| Kidney                                |         | 18       | V12Gy < 55%<br>V20Gy< 30%<br>V28Gy< 20% |                          |
| Liver                                 |         | 30       |   |                          |
| Intestine/Stomach (peritoneal cavity) | 50      |          | V45Gy <195CC                            |                          |
| Heart                                 |         |          | V25Gy <10%                              |                          |

# 3D-CRT PLANNING: PANCREAS CASE




# 3D-CRT PLANNING: PANCREAS CASE

## 1° Plan:PTV45




# 3D-CRT PLANNING: PANCREAS CASE

## I° Plan:PTV45



# 3D-CRT PLANNING: PANCREAS CASE

## I° Plan:PTV45





# 3D-CRT PLANNING: PANCREAS CASE


## II° Plan:PTV54






# 3D-CRT PLANNING: PANCREAS CASE

## Plan Sum




# 3D-CRT PLANNING: PANCREAS CASE

## Plan Sum




THANKS FOR THE ATTENTION

penile anatomy  
mid sagittal




## PROSTATE



| PTV | Prescription | N° fraction | Dose for Fraction |
|-----|--------------|-------------|-------------------|
| PTV | 70 Gy        | 35          | 1.8 Gy            |

| OAR          | Dmax<br>Gy | Dmean<br>Gy | Constraints                         | Other, if it is possible |
|--------------|------------|-------------|-------------------------------------|--------------------------|
| Rectum       |            |             | V65Gy<25%<br>V60Gy<35%<br>V50Gy<50% |                          |
| Bladder      |            |             | V65Gy<50%                           |                          |
| Femoral Head |            |             | V50Gy<5%                            |                          |
| Penile bulb  |            | 50          |                                     |                          |



|   |              |          |            |
|---|--------------|----------|------------|
| ■ | Vescica      | Approved | PROSTATA 2 |
| ▲ | Vescica      | Approved | PROSTATA 1 |
| ■ | Testa Fem Sn | Approved | PROSTATA 2 |
| ▲ | Testa Fem Sn | Approved | PROSTATA 1 |
| ■ | Testa Fem Dx | Approved | PROSTATA 2 |
| ▲ | Testa Fem Dx | Approved | PROSTATA 1 |
| ■ | Retto        | Approved | PROSTATA 2 |
| ▲ | Retto        | Approved | PROSTATA 1 |
| ■ | PTV          | Approved | PROSTATA 2 |
| ▲ | PTV          | Approved | PROSTATA 1 |

7 FIELDS –  
PROSTATA 1

6 FIELDS –  
PROSTATA 2

PATIENT SET UP


**HEAD**







## ORGAN AT RISK

## EYES



| Site         | Damage      | Dose     |
|--------------|-------------|----------|
| lens         | cataract    | 6-12 Gy  |
| cornea       | keratitis   | 50 Gy    |
| retina       | vision loss | 45-50 Gy |
| optic chiasm | vision loss | 50 cGy   |

[http://www.aboutcancer.com/radiation\\_to\\_the\\_eye.htm](http://www.aboutcancer.com/radiation_to_the_eye.htm)



| Site            | Dose  |
|-----------------|-------|
| PITUITARY GLAND | 50 Gy |

ORGAN AT RISK

EARS





Site

Dose

COCLEA

Dmean<45Gy  
better 35Gy

These doses may not apply in patients who have received radiotherapy combined with concurrent/adjuvant chemotherapy.




Site

Dose

BRAINSTEM

D1-100CC<59Gy  
D100%<54Gy

Dpermanent alopecia>43 Gy






# BRAIN



| PTV | Prescription | N° fraction | Dose for Fraction |
|-----|--------------|-------------|-------------------|
| PTV | 60 Gy        | 30          | 2Gy               |

| OAR             | Dmax Gy | Dmean Gy | Constraints | Other, if it is possible |
|-----------------|---------|----------|-------------|--------------------------|
| Lens            | 6       |          |             |                          |
| Eyes (retina)   | 50      |          |             |                          |
| Brainstem       | 54      |          |             | Dmax<50Gy                |
| Optical Chiasm  | 55      | 50       |             | Dmax<45Gy                |
| pituitary gland | 55      |          |             | Dmax<45Gy                |
| Optical nerve   | 55      | 50       |             | Dmax<45Gy                |

- Treatment technique: coplanar and no-coplanar fields



| PTV | Prescription | N° fraction | Dose for Fraction |
|-----|--------------|-------------|-------------------|
| PTV | 60 Gy        | 30          | 2 Gy              |

| OAR                | Dmax Gy | Dmean Gy | Constraints                            | Other, if it is possible |
|--------------------|---------|----------|--|--------------------------|
| Heart              |         |          | $V_{30Gy} < 46\%$                      | $V_{25Gy} < 10\%$        |
| Lung omolateral    |         |          | $V_{20Gy} < 30-40\%$                   | $V_{20Gy} < 20\%$        |
| Lung controlateral |         |          | $V_{20Gy} < 20\%$<br>$V_{5Gy} < 42\%$  |                          |
| Spinal coord       | 50      |          |  | $D_{max} < 45Gy$         |
| Esophagus          | 74      |          | $V_{50Gy} < 40\%$<br>$V_{35Gy} < 50\%$ |                          |